Pfizer Inc. (NYSE:PFE) Stock Position Increased by Frank Rimerman Advisors LLC

Key Points

• Frank Rimerman Advisors LLC significantly increased its position in Pfizer, lifting it by 535.5% to hold 140,593 shares worth approximately $3.56 million.
• Pfizer recently reported $0.78 EPS for its latest quarter, exceeding estimates and showing a 10.3% year-over-year revenue growth to $14.65 billion.
• Pfizer announced a quarterly dividend of $0.43, which translates to an annualized yield of 7.0%, with a payout ratio of 91.49%.

Frank Rimerman Advisors LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 535.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 140,593 shares of the biopharmaceutical company's stock after buying an additional 118,471 shares during the period. Frank Rimerman Advisors LLC's holdings in Pfizer were worth $3,563,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Koss Olinger Consulting LLC raised its stake in shares of Pfizer by 4.4% in the 1st quarter. Koss Olinger Consulting LLC now owns 83,970 shares of the biopharmaceutical company's stock worth $2,128,000 after buying an additional 3,569 shares in the last quarter. Arcadia Wealth Management Inc. raised its stake in shares of Pfizer by 16.6% in the 1st quarter. Arcadia Wealth Management Inc. now owns 23,150 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 3,300 shares in the last quarter. Donoghue Forlines LLC bought a new stake in shares of Pfizer in the 1st quarter worth $1,434,000. Zions Bancorporation National Association UT bought a new stake in shares of Pfizer in the 1st quarter worth $6,972,000. Finally, Townsquare Capital LLC grew its holdings in shares of Pfizer by 34.3% in the 1st quarter. Townsquare Capital LLC now owns 549,692 shares of the biopharmaceutical company's stock worth $13,929,000 after acquiring an additional 140,342 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.57 on Friday. The business's 50-day moving average price is $24.44 and its two-hundred day moving average price is $24.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.96. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a market capitalization of $139.69 billion, a P/E ratio of 13.07, a price-to-earnings-growth ratio of 0.87 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the company posted $0.60 earnings per share. The business's quarterly revenue was up 10.3% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's payout ratio is 91.49%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Jefferies Financial Group lifted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. Finally, BMO Capital Markets decreased their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.